Nicolas Garel
Overview
Explore the profile of Nicolas Garel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
58
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garel N, Greenway K, Lavin P, Pike C, Pike W, Hyde R, et al.
J Addict Med
. 2025 Feb;
PMID: 39961096
Objectives: Individuals with stimulant use disorders (StSUDs) present an elevated risk of cardiovascular complications compared with the general population. However, it remains unclear whether, within the subpopulation of individuals with...
2.
Diep D, de la Salle S, Thibault Levesque J, Lifshitz M, Garel N, Greenway K
Expert Rev Clin Pharmacol
. 2025 Jan;
18(3):109-129.
PMID: 39868914
Introduction: Since its synthesis in 1962, ketamine has been widely used in diverse medical contexts, from anesthesia to treatment-resistant depression. However, interpretations of ketamine's subjective effects remain polarized. Biomedical frameworks...
3.
Garel N, Dols A, Yu J, Cresce C, Rej S, Sajatovic M
Am J Geriatr Psychiatry
. 2025 Jan;
33(4):372-386.
PMID: 39855966
Objectives: To evaluate cariprazine in adults with older- and younger-age bipolar I disorder (OABD-I and YABD-I) and compare treatment effects between them. Design And Setting: Pooled post-hoc analysis of studies...
4.
Longpre-Poirier C, Miron J, Garel N, Samson-Daoust E, Rizkallah E, Desbeaumes Jodoin V, et al.
Psychiatry Res
. 2024 Aug;
340:116122.
PMID: 39137557
This cohort study investigated whether allostatic load (AL) is associated with treatment response to repetitive transcranial magnetic stimulation (rTMS) in treatment-resistant depression (TRD). Pre-treatment blood samples measured AL across multiple...
5.
Elkrief L, Sharafi H, Bakouni H, McAnulty C, Bastien G, Dubreucq S, et al.
Can J Psychiatry
. 2024 Jul;
69(11):793-805.
PMID: 39033427
Introduction: Amphetamine-type stimulants (ATSs) are related to significant harm worldwide, with limited effective pharmacological treatments for ATS use disorder (ATSUD). Modafinil has been explored as a potential treatment for ATSUD....
6.
de la Salle S, Kettner H, Thibault Levesque J, Garel N, Dames S, Patchett-Marble R, et al.
Sci Rep
. 2024 Jul;
14(1):16524.
PMID: 39019922
Recent clinical trials have found that the serotonergic psychedelic psilocybin effectively alleviates anxiodepressive symptoms in patients with life-threatening illnesses when given in a supportive environment. These outcomes prompted Canada to...
7.
Garel N, Brodsky K, Ostacher M
Alcohol Alcohol
. 2024 Jun;
59(4).
PMID: 38938218
Alcohol use disorder poses a significant global health threat, with profound consequences for individuals, families, and communities, necessitating continued exploration of novel treatment approaches. Acceptance and Commitment Therapy, an evidence-based...
8.
Richard-Devantoy S, Berlim M, Garel N, Inja A, Turecki G
J Affect Disord
. 2024 Jun;
361:425-433.
PMID: 38823590
Background: A more in-depth understanding of the relationship between depressive symptoms, neurocognition and suicidal behavior could provide insights into the prognosis and treatment of major depressive disorder (MDD) and suicide....
9.
Guay E, Brouillette M, Drury J, Garel N, Greenway K
J Clin Psychopharmacol
. 2024 Feb;
44(2):196-198.
PMID: 38421927
No abstract available.
10.
Greenway K, Garel N, Dinh-Williams L, Beaulieu S, Turecki G, Rej S, et al.
JAMA Netw Open
. 2024 Feb;
7(2):e2354719.
PMID: 38315489
No abstract available.